Jonathan D. Campbell

发表

Does the use of efficacy or effectiveness evidence in cost-effectiveness analyses matter?

Nathorn Chaiyakunapruk, P. Dilokthornsakul, Jonathan D. Campbell, 2015 .

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States

David Veenstra, Josh J. Carlson, Anirban Basu, 2019, PharmacoEconomics.

Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes

Jonathan D. Campbell, S. Ellis, R. McQueen, 2011, Cost effectiveness and resource allocation : C/E.

Exploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire.

Jonathan D. Campbell, D. Magid, B. Bender, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Measuring the effect of asthma control on exacerbations and health resource use.

Jonathan D. Campbell, M. Schatz, D. Magid, 2015, Journal of Allergy and Clinical Immunology.

Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation

Jonathan D. Campbell, P. Sullivan, V. Ghushchyan, 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

Hospital-Acquired Pressure Ulcers at Academic Medical Centers in the United States, 2008-2012: Tracking Changes Since the CMS Nonpayment Policy.

Jonathan D Campbell, William V Padula, Manish K. Mishra, 2015, Joint Commission journal on quality and patient safety.

The prevalence of MS in the United States

Ruth Ann Marrie, Helen Tremlett, Stephen L. Buka, 2019, Neurology.

Asthma outcomes: healthcare utilization and costs.

Jonathan D. Campbell, L. Akinbami, Robert A. Smith, 2012, The Journal of allergy and clinical immunology.

The Costs of Treating Breast Cancer in the US

Scott D. Ramsey, Jonathan D. Campbell, S. Ramsey, 2012, PharmacoEconomics.

Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value.

Jonathan D. Campbell, A. Briggs, P. Raggi, 2018, Health affairs.

Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation

Jonathan D. Campbell, R. Hansen, P. Dilokthornsakul, 2016, European Respiratory Journal.

Fair global drug pricing

Jonathan D. Campbell, Z. Kaló, Jonathan D. Campbell, 2018, Expert review of pharmacoeconomics & outcomes research.

Increasing pharmaceutical copayments: impact on asthma medication utilization and outcomes.

Jonathan D. Campbell, S. Sullivan, S. Sajjan, 2011, The American journal of managed care.

Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years.

Jonathan D. Campbell, L. Garrison, J. Zerzan, 2013, Clinical therapeutics.

Cost and Reimbursement of Providing Routine Vaccines in Outpatient Obstetrician/Gynecologist Settings.

Jonathan D. Campbell, S. O'leary, A. Dempsey, 2020, American journal of obstetrics and gynecology.

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

Jonathan D. Campbell, J. Tice, S. Pearson, 2018, JAMA pediatrics.

The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies

Jonathan D. Campbell, N. Papadopoulos, N. Roche, 2019, Clinical and Translational Allergy.

Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

Jonathan D. Campbell, R. McQueen, M. Whittington, 2019, PharmacoEconomics.

The direct and indirect costs of Dravet Syndrome

Jonathan D. Campbell, K. Knupp, A. Gammaitoni, 2018, Epilepsy & Behavior.

Validation of an algorithm for identifying MS cases in administrative health claims datasets

Jonathan D. Campbell, M. Wallin, R. Marrie, 2019, Neurology.

Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

Jonathan D. Campbell, J. Tice, S. Pearson, 2019, JAMA network open.

Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis

Jonathan D. Campbell, M. Cordero-Coma, W. Padula, 2015, Journal of health economics and outcomes research.

Frequency of Continuous Glucose Monitoring Use and Change in Hemoglobin A1C for Adults with Type 1 Diabetes in a Clinical Practice Setting.

Jonathan D. Campbell, D. Maahs, S. Ellis, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric & Young Adult Population: A Case-Control Study.

Jonathan D. Campbell, D. Ghosh, Angela S Czaja, 2020, The Journal of pediatrics.

Impact of Nonmedical Vaccine Exemption Policies on the Health and Economic Burden of Measles.

Jonathan D. Campbell, A. Dempsey, A. Kempe, 2017, Academic pediatrics.

Value of Information in Asia: Concepts, Current Use, and Future Directions.

Jonathan D. Campbell, E. Spackman, R. McQueen, 2016, Value in health regional issues.

Comparative Effectiveness of Quality Improvement Interventions for Pressure Ulcer Prevention in Hospitals

Manish K. Mishra, Jonathan D. Campbell, M. Makic, 2014 .

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada

Jonathan D. Campbell, M. Breton, R. McQueen, 2016, Journal of diabetes science and technology.

Treatment patterns and related clinical consequences in adults with asthma

Jonathan D. Campbell, A. Thompson, P. Dilokthornsakul, 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations

Jonathan D. Campbell, J. V. van Boven, Danielle N. Sheehan, 2018, PharmacoEconomics.

Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis*

Jonathan D. Campbell, A. Atherly, R. Lindrooth, 2017, Critical care medicine.

Multiple sclerosis prevalence in the United States commercially insured population

Jonathan D. Campbell, K. Nair, R. Valuck, 2016, Neurology.

Centralized Reminder/Recall to Increase Influenza Vaccination Rates: A Two-State Pragmatic Randomized Trial.

Jonathan D. Campbell, C. Tseng, P. Szilagyi, 2019, Academic pediatrics.

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19

Jonathan D. Campbell, D. Rind, S. Pearson, 2022, Value in Health.

Endemic mycoses in patients with STAT3- mutated hyper-IgE (Job) syndrome

Jonathan D. Campbell, M. Schatz, D. Magid, 2015 .

Economic and clinical burden of comorbidities among patients with acromegaly.

Jonathan D. Campbell, A. Ribeiro-Oliveira, M. Whittington, 2021, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Risk Factors of Prescription Opioid Overdose Among Colorado Medicaid Beneficiaries.

Jonathan D. Campbell, R. Page, J. Zerzan, 2016, The journal of pain : official journal of the American Pain Society.

Meeting abstracts from the Respiratory Effectiveness Group 2015 Winter Summit – databases and registries around the world: maximizing the yield

Jonathan D. Campbell, D. Postma, C. Rand, 2015, Pragmatic and Observational Research.

Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation

Jonathan D. Campbell, P. Sullivan, V. Ghushchyan, 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

Grace A Lin, Jonathan D. Campbell, D. Rind, 2022, Neurology.

Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke

Jonathan D. Campbell, J. Burke, M. Leppert, 2015, Stroke.

Cost-Effectiveness Uncertainty Analysis Methods

Jonathan D. Campbell, A. Briggs, J. Carlson, 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications.

Jonathan D. Campbell, M. Whittington, R. McQueen, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic grand rounds: psychological distress and depression associated with job loss and gain: the social costs of job instability.

Jonathan D. Campbell, R. McQueen, V. Ghushchyan, 2010, Psychiatric services.

Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder.

Jonathan D. Campbell, S. Sullivan, J. Kowalski, 2010, Urology.

Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes

Jonathan D. Campbell, A. Briggs, S. Sullivan, 2010, Quality of Life Research.

Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant Infections

Jonathan D. Campbell, Meghan N. Jeffres, Monica L. Bianchini, 2020, Hospital pharmacy.

Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries.

András Inotai, Zoltán Kaló, Bertalan Németh, 2019, Journal of comparative effectiveness research.

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Prasun Subedi, Richard L Schilsky, James Wu, 2019, Journal of Immunotherapy for Cancer.

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence

Jonathan D. Campbell, R. Dmochowski, S. Sullivan, 2009, BMC urology.

Disease-specific reference equations for lung function in patients with cystic fibrosis.

Jonathan D. Campbell, R. Kronmal, R. Gibson, 2005, American journal of respiratory and critical care medicine.

Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?

Michael Drummond, Jonathan Campbell, Jonathan D. Campbell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver survey

Jonathan D. Campbell, K. Knupp, A. Gammaitoni, 2018, Epilepsy & Behavior.

Cost-effectiveness of renin-guided treatment of hypertension.

Jonathan D. Campbell, Steven M. Smith, Jonathan D. Campbell, 2013, American journal of hypertension.

Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis

Jonathan D. Campbell, W. Padula, Shiona Heru, 2016, Journal of General Internal Medicine.

Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis.

Jonathan D. Campbell, P. Molina, J. Klein, 2005, American journal of respiratory and critical care medicine.

Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet

Jonathan D. Campbell, V. Belozeroff, S. Chiroli, 2013, Journal of medical economics.

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy.

Jonathan D. Campbell, D. Ollendorf, M. Whittington, 2018, JAMA oncology.

Paying for CAR-T Therapy Amidst Limited Health System Resources.

Jonathan D. Campbell, M. Whittington, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.

Mike Thomas, Ian D Pavord, Jonathan D Campbell, 2015, The Lancet. Respiratory medicine.

RAISED BLOOD EOSINOPHIL LEVELS AS AN INDICATOR OF PROSPECTIVE ASTHMA OUTCOMES

Jonathan D. Campbell, I. Pavord, D. Price, 2013 .

Comparison of HIV Screening Strategies in the Emergency Department

Matthew F. Toerper, Jonathan D. Campbell, M. Saheed, 2021, JAMA network open.

Comparative effectiveness of quality improvement interventions for pressure ulcer prevention in academic medical centers in the United States.

Jonathan D Campbell, William V Padula, Manish K. Mishra, 2015, Joint Commission journal on quality and patient safety.

Is Prevalence of Atherosclerotic Risk Factors Increasing Among Young Adults? It Depends on How You Ask

Jonathan D. Campbell, P. Ho, S. Sillau, 2019, Journal of the American Heart Association.

Effect of State Immunization Information System Based Reminder/Recall for Influenza Vaccinations: A Randomized Trial of Autodialer, Text, and Mailed Messages.

Jonathan D. Campbell, S. Humiston, C. Tseng, 2020, The Journal of pediatrics.

Brief Report: Validation of a Quantitative HIV Risk Prediction Tool Using a National HIV Testing Cohort

Jonathan D. Campbell, M. Lyons, J. Haukoos, 2015, Journal of acquired immune deficiency syndromes.

PRM47 Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information

Jonathan D. Campbell, A. Briggs, E. Spackman, 2011 .

Community Health Worker Home Visits for Medicaid-Enrolled Children With Asthma: Effects on Asthma Outcomes and Costs.

Jonathan D. Campbell, P. Hosokawa, Lin Song, 2015, American journal of public health.

Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates

Jonathan D. Campbell, S. Humiston, C. Tseng, 2020, Pediatrics.

Guidance toward the implementation of multicriteria decision analysis framework in developing countries

András Inotai, Zoltán Kaló, Bertalan Németh, 2018, Expert review of pharmacoeconomics & outcomes research.

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.

Jonathan D. Campbell, T. Vollmer, K. Nair, 2014, Multiple sclerosis and related disorders.

Value of Public Health Funding in Preventing Hospital Bloodstream Infections in the United States

Jonathan D. Campbell, A. Atherly, R. Lindrooth, 2017, American journal of public health.

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England

Jonathan D. Campbell, M. Breton, R. McQueen, 2018, Journal of diabetes science and technology.

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Jonathan D. Campbell, J. Tice, S. Pearson, 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma.

Jonathan D. Campbell, P. Sullivan, V. Ghushchyan, 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Managed care opportunities for improving asthma care.

Jonathan D. Campbell, 2011, The American journal of managed care.

Cost effectiveness of New Hepatitis C Therapies

Jonathan D. Campbell, R. McQueen, P. Dilokthornsakul, 2015 .

Economic Differences in Direct and Indirect Costs Between People With Epilepsy and Without Epilepsy

Jonathan D. Campbell, R. McQueen, V. Ghushchyan, 2012, Medical care.

Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.

Jonathan D. Campbell, T. Vollmer, R. McQueen, 2015, Journal of managed care & specialty pharmacy.

Incorporating real-world clinical practice in multiple sclerosis economic evaluations

Jonathan D. Campbell, T. Vollmer, K. Nair, 2015, Expert review of pharmacoeconomics & outcomes research.

Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

Jonathan D. Campbell, N. Papadopoulos, N. Roche, 2019, Clinical and Translational Allergy.

Measuring the cost of poor asthma control and exacerbations

Jonathan D. Campbell, D. Magid, B. Bender, 2017, The Journal of asthma : official journal of the Association for the Care of Asthma.

Centralized Reminder/Recall for Human Papillomavirus Vaccination: Findings From Two States-A Randomized Clinical Trial.

Jonathan D. Campbell, S. Humiston, C. Tseng, 2021, Journal of Adolescent Health.

Programmatic Cost Evaluation of Nontargeted Opt-Out Rapid HIV Screening in the Emergency Department

Amy A. Conroy, Jonathan D. Campbell, J. Haukoos, 2013, PloS one.

Increased Adoption of Quality Improvement Interventions to Implement Evidence-Based Practices for Pressure Ulcer Prevention in U.S. Academic Medical Centers.

Jonathan D Campbell, William V Padula, Manish K. Mishra, 2015, Worldviews on evidence-based nursing.

Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature

Jonathan D. Campbell, David O. Yamamoto, Jonathan D. Campbell, 2012, Autoimmune diseases.

Pharmacoeconomics and outcomes research degree-granting PhD programs in the United States.

Jonathan D. Campbell, K. Nair, R. Valuck, 2013, Research in social & administrative pharmacy : RSAP.

Achieving high value care for all and the perverse incentives of 340B price agreements

Jonathan D. Campbell, M. Whittington, R. McQueen, 2018, Neurology. Clinical practice.

Screening test recommendations for methicillin‐resistant Staphylococcus aureus surveillance practices: A cost‐minimization analysis

Jonathan D. Campbell, A. Atherly, R. Lindrooth, 2017, American journal of infection control.

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.

Jonathan D. Campbell, P. Dilokthornsakul, M. Patidar, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma.

Jonathan D. Campbell, S. Sullivan, D. Blough, 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?

Jonathan D. Campbell, J. V. van Boven, P. Dilokthornsakul, 2017, The journal of allergy and clinical immunology. In practice.

Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?

Jonathan D. Campbell, N. Chaiyakunapruk, P. Dilokthornsakul, 2017, The Journal of asthma : official journal of the Association for the Care of Asthma.

Dynamic medication adherence modeling in primary prevention of cardiovascular disease: a Markov microsimulation methods application.

Jonathan D. Campbell, P. Ho, K. Nair, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Association Between Glycated Hemoglobin and Health Utility for Type 1 Diabetes

Jonathan D. Campbell, D. Maahs, S. Ellis, 2014, The Patient - Patient-Centered Outcomes Research.

CommunityHealthWorkerHomeVisits forMedicaid-Enrolled Children With Asthma : Effects on Asthma Outcomes and Costs

Jonathan D. Campbell, P. Hosokawa, Lin Song, 2016 .

CommunityHealthWorkerHomeVisitsforMedicaid-Enrolled ChildrenWithAsthma:EffectsonAsthma OutcomesandCosts

Jonathan D. Campbell, P. Hosokawa, Lin Song, 2015 .